Wockhardt BioAg

Wockhardt Bio AG is a Switzerland-based global pharmaceutical and biotechnology company and a key subsidiary of India's Wockhardt Limited. The company is primarily focused on the development, manufacturing, and marketing of pharmaceutical and biopharmaceutical formulations, with a strong emphasis on novel antibiotics to combat antimicrobial resistance (AMR). Its portfolio includes a wide range of generic drugs, biosimilars (such as insulin glargine), and proprietary New Chemical Entities (NCEs) like Zaynich (cefepime/zidebactam) and Miqnaf (nafithromycin). Wockhardt Bio AG manages Wockhardt's international business operations across the US, Europe, the Middle East, and Latin America, utilizing advanced manufacturing facilities in Ireland, the UK, and Dubai.